- Home
- TERN
as 11-12-2025 3:44pm EST
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 710.6M | IPO Year: | 2021 |
| Target Price: | $21.19 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.86 - $21.12 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Terns Pharmaceuticals Inc. (TERN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Quigley Jill M. | TERN | Director | Nov 4 '25 | Sell | $18.00 | 24,520 | $441,360.00 | 0 | |
| Kuriakose Emil | TERN | Chief Medical Officer | Oct 1 '25 | Sell | $7.85 | 944 | $7,407.00 | 51,520 |
Latest Terns Pharmaceuticals Inc. News
TERN Breaking Stock News: Dive into TERN Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Barclays Initiates Terns Pharmaceuticals at Overweight With $15 Price Target
MT Newswires
5 months ago
Terns Pharmaceuticals Reports Positive Phase 1 Results for Oral Weight Loss Drug
GlobeNewswire
5 months ago
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
GlobeNewswire
5 months ago
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
GlobeNewswire
6 months ago
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
Insider Monkey
6 months ago
Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030?
GlobeNewswire
6 months ago
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
6 months ago
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Compare TERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TERN Terns Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.